4-(N,N-dipropylsulfamoyl)-N-(pyridin-4-yl)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(N,N-dipropylsulfamoyl)-N-(pyridin-4-yl)benzamide
• 英文别名: 4-(dipropylsulfamoyl)-N-pyridin-4-ylbenzamide
• 化学式: C₁₈H₂₃N₃O₃S
• 分子量: 361.465
• InChiKey: SBNZSOLFRZIOSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  87.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-氨基吡啶 、 丙磺舒 在 N,N'-羰基二咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以48%的产率得到4-(N,N-dipropylsulfamoyl)-N-(pyridin-4-yl)benzamide
  参考文献：
  名称：

  New amide derivatives of Probenecid as selective inhibitors of carbonic anhydrase IX and XII: Biological evaluation and molecular modelling studies

  摘要：

  Novel amide derivatives of Probenecid were synthesized and discovered to act as potent and selective inhibitors of the human carbonic anhydrase (hCA, EC 4.2.1.1) transmembrane isoforms hCA IX and XII. The proposed chemical transformation of the carboxylic acid into an amide group led to a complete loss of hCA I and II inhibition (K(i)s > 10,000 nM) and enhanced the inhibitory activity against hCA IX and XII, with respect to the parent compound (incorporating a COOH function). These promising biological results have been corroborated by molecular modelling studies within the active sites of the four studied human carbonic anhydrases, which enabled us to rationalize both the isoform selectivity and high activity against the tumor-associated isoforms hCA IX/XII. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.05.013

文献信息

• New amide derivatives of Probenecid as selective inhibitors of carbonic anhydrase IX and XII: Biological evaluation and molecular modelling studies
  作者：Simone Carradori、Adriano Mollica、Mariangela Ceruso、Melissa D’Ascenzio、Celeste De Monte、Paola Chimenti、Rocchina Sabia、Atilla Akdemir、Claudiu T. Supuran

  DOI：10.1016/j.bmc.2015.05.013

  日期：2015.7

  Novel amide derivatives of Probenecid were synthesized and discovered to act as potent and selective inhibitors of the human carbonic anhydrase (hCA, EC 4.2.1.1) transmembrane isoforms hCA IX and XII. The proposed chemical transformation of the carboxylic acid into an amide group led to a complete loss of hCA I and II inhibition (K(i)s > 10,000 nM) and enhanced the inhibitory activity against hCA IX and XII, with respect to the parent compound (incorporating a COOH function). These promising biological results have been corroborated by molecular modelling studies within the active sites of the four studied human carbonic anhydrases, which enabled us to rationalize both the isoform selectivity and high activity against the tumor-associated isoforms hCA IX/XII. (C) 2015 Elsevier Ltd. All rights reserved.